9 results on '"McGuire, Darren K."'
Search Results
2. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
- Author
-
Bhatt, Ankeet S., Bhatt, Deepak L., Steg, Ph Gabriel, Szarek, Michael, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Testani, Jeffrey M., Wilcox, Christopher S., Davies, Michael, Pitt, Bertram, and Kosiborod, Mikhail N.
- Subjects
- *
TYPE 2 diabetes , *HEART failure patients , *VENTRICULAR ejection fraction , *HEART failure , *SODIUM-glucose cotransporter 2 inhibitors ,CARDIOVASCULAR disease related mortality - Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the effects of SGLT1 and SGLT2 inhibition on health status are unknown. These prespecified analyses of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial examined the effects of sotagliflozin vs placebo on HF-related health status. SOLOIST-WHF randomized patients hospitalized or recently discharged after a worsening HF episode to receive sotagliflozin or placebo. The primary endpoint was total number of HF hospitalizations, urgent HF visits, and cardiovascular death. Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score was a prespecified secondary endpoint. This analysis evaluated change in the KCCQ-12 score from baseline to month 4. Of 1,222 patients randomized, 1,113 (91%) had complete KCCQ-12 data at baseline and 4 months. The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups. Sotagliflozin vs placebo reduced the risk of the primary endpoint consistently across KCCQ-12 tertiles (P trend = 0.54). Sotagliflozin-treated patients vs those receiving placebo experienced modest improvement in KCCQ-12 at 4 months (adjusted mean change: 4.1 points; 95% CI: 1.3-7.0 points; P = 0.005). KCCQ-12 improvements were consistent across prespecified subgroups, including left ventricular ejection fraction <50% or ≥50%. More patients receiving sotagliflozin vs those receiving placebo had at least small (≥5 points) improvements in KCCQ-12 at 4 months (OR: 1.38; 95% CI: 1.06-1.80; P = 0.017). Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
- Author
-
Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., McGuire, Darren K., Inzucchi, Silvio E., Lopes, Renato D., Davies, Michael J., Banks, Phillip, Pitt, Bertram, and Steg, Philippe Gabriel
- Subjects
- *
TYPE 2 diabetes , *GLYCOSYLATED hemoglobin , *PROPORTIONAL hazards models , *HEMOGLOBINS , *ADULTS - Abstract
The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trials demonstrated that sotagliflozin, an SGLT1 and SGLT2 inhibitor, improves outcomes in individuals with type 2 diabetes who have heart failure (HF) or kidney disease. We assessed the efficacy of sotagliflozin on HF clinical outcomes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels. We included all adults from SCORED and SOLOIST-WHF. The primary outcome was a composite of cardiovascular death, hospitalizations for HF, and urgent visits for HF. The efficacy of sotagliflozin compared with placebo was evaluated by baseline HbA1c using competing-risk marginal proportional hazards models. We identified 11,744 adults. Individuals with HbA1c ≤7.5% experienced the primary outcome at a lower rate in the sotagliflozin group (11.2 per 100 person-years) than the placebo group (15.5 per 100 person-years) (HR: 0.73; 95% CI: 0.57-0.93). Similarly, individuals with HbA1c of 7.6% to 9.0% experienced the primary outcome at a lower rate in the sotagliflozin group (7.3 per 100 person-years) than the placebo group (9.4 per 100 person-years) (HR: 0.77; 95% CI: 0.63-0.96). These findings were also consistent among individuals with HbA1c >9.0%, with a primary outcome rate in the sotagliflozin group (7.8 per 100 person-years) that was lower than the placebo group (11.6 per 100 person-years) (HR: 0.65; 95% CI: 0.50-0.84). The efficacy of sotagliflozin was consistent by baseline HbA1c level (P for interaction = 0.58). In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL.
- Author
-
Pandey, Ambarish, Kolkailah, Ahmed A., McGuire, Darren K., Frederich, Robert, Cater, Nilo B., Cosentino, Francesco, Liu, Jie, Pratley, Richard, Dagogo-Jack, Samuel, Cherney, David Z.I., Wynant, Willy, Mancuso, James, Masiukiewicz, Urszula, and Cannon, Christopher P.
- Subjects
- *
TYPE 2 diabetes , *HEART failure , *CARDIOVASCULAR diseases - Published
- 2023
- Full Text
- View/download PDF
5. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.
- Author
-
Rao, Vishal N., Murray, Evan, Butler, Javed, Cooper, Lauren B., Cox, Zachary L., Fiuzat, Mona, Green, Jennifer B., Lindenfeld, JoAnn, McGuire, Darren K., Nassif, Michael E., O'Brien, Cara, Pagidipati, Neha, Sharma, Kavita, Vaduganathan, Muthiah, Vardeny, Orly, Fonarow, Gregg C., Mentz, Robert J., and Greene, Stephen J.
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *MEDICAL personnel , *BLOOD pressure , *DRUGS , *GASTRIC inhibitory polypeptide , *ACE inhibitors - Abstract
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.
- Author
-
Segar, Matthew W., Khan, Muhammad Shahzeb, Patel, Kershaw V., Butler, Javed, Tang, W.H. Wilson, Vaduganathan, Muthiah, Lam, Carolyn S.P., Verma, Subodh, McGuire, Darren K., and Pandey, Ambarish
- Subjects
- *
PROGNOSIS , *CARDIOVASCULAR diseases , *CHRONIC kidney failure , *CARDIOMYOPATHIES , *HEART failure , *BLOOD sugar analysis , *GLOMERULAR filtration rate , *BIOLOGICAL models , *RESEARCH , *DIABETIC cardiomyopathy , *AGE distribution , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *TYPE 2 diabetes , *COMPARATIVE studies , *DISEASE prevalence , *BODY mass index , *LONGITUDINAL method - Abstract
Background: Diabetes is associated with abnormalities in cardiac remodeling and high risk of heart failure (HF).Objectives: The purpose of this study was to evaluate the prevalence and prognostic implications of diabetes with cardiomyopathy (DbCM) among community-dwelling individuals.Methods: Adults without prevalent cardiovascular disease or HF were pooled from 3 cohort studies (ARIC [Atherosclerosis Risk In Communities], CHS [Cardiovascular Health Study], CRIC [Chronic Renal Insufficiency Cohort]). Among participants with diabetes, DbCM was defined using different definitions: 1) least restrictive: ≥1 echocardiographic abnormality (left atrial enlargement, left ventricle hypertrophy, diastolic dysfunction); 2) intermediate restrictive: ≥2 echocardiographic abnormalities; and 3) most restrictive: elevated N-terminal pro-B-type natriuretic peptide levels (>125 in normal/overweight or >100 pg/mL in obese) plus ≥2 echocardiographic abnormalities. Adjusted Fine-Gray models were used to evaluate the risk of HF.Results: Among individuals with diabetes (2,900 of 10,208 included), the prevalence of DbCM ranged from 67.0% to 11.7% in the least and most restrictive criteria, respectively. Higher fasting glucose, body mass index, and age as well as worse kidney function were associated with higher risk of DbCM. The 5-year incidence of HF among participants with DbCM ranged from 8.4%-12.8% in the least and most restrictive definitions, respectively. Compared with euglycemia, DbCM was significantly associated with higher risk of incident HF with the highest risk observed for the most restrictive definition of DbCM (HR: 2.55 [95% CI: 1.69-3.86]; least restrictive criteria HR: 1.99 [95% CI: 1.50-2.65]). A similar pattern of results was observed across cohort studies, across sex and race subgroups, and among participants without hypertension or obesity.Conclusions: Regardless of the criteria used to define cardiomyopathy, DbCM identifies a high-risk subgroup for developing HF. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION.
- Author
-
Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew, McGarrah, Robert, Jones, Philip, Kwee, Lydia, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael, Newgard, Christopher B., Borlaug, Barry, Kitzman, Dalane W., Shah, Sanjiv Jayendra, Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Lanfear, David E., Javaheri, Ali, and Umpierrez, Guillermo
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN - Published
- 2024
- Full Text
- View/download PDF
8. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
- Author
-
Greene, Stephen J., Vaduganathan, Muthiah, Khan, Muhammad Shahzeb, Bakris, George L., Weir, Matthew R., Seltzer, Jonathan H., Sattar, Naveed, McGuire, Darren K., Januzzi, James L., Stockbridge, Norman, and Butler, Javed
- Subjects
- *
HEART failure , *HEART diseases , *DRUG approval , *CARDIOVASCULAR agents - Abstract
Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Biomarkers of Chronic Cardiac Injury and Hemodynamic Stress Identify a Malignant Phenotype of Left Ventricular Hypertrophy in the General Population
- Author
-
Neeland, Ian J., Drazner, Mark H., Berry, Jarett D., Ayers, Colby R., deFilippi, Christopher, Seliger, Stephen L., Nambi, Vijay, McGuire, Darren K., Omland, Torbjørn, and de Lemos, James A.
- Subjects
- *
BIOMARKERS , *HEMODYNAMICS , *LEFT heart ventricle , *CARDIAC hypertrophy , *MYOCARDIUM , *HEART failure risk factors , *CAUSES of death , *WOUNDS & injuries - Abstract
Objectives: The goal of this study was to determine if biomarkers of subclinical myocardial injury and hemodynamic stress identify asymptomatic individuals with left ventricular hypertrophy (LVH) at higher risk for heart failure (HF) and death. Background: The interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) on cardiovascular (CV) outcomes in the general population is unknown. Methods: Participants in the Dallas Heart Study without clinical HF, LV dysfunction, or chronic kidney disease underwent measurement of LV mass by magnetic resonance imaging (MRI), cTnT by highly sensitive assay, and NT-proBNP analysis (n = 2,413). Subjects were stratified according to LVH and by detectable cTnT (≥3 pg/ml) and increased NT-proBNP (>75th age- and sex-specific percentile) levels. For each analysis, participants were categorized into groups based on the presence (+) or absence (–) of LVH and biomarker levels above (+) or below (–) the predefined threshold. Results: Nine percent of participants were LVH+, 25% cTnT+, and 24% NT-proBNP+. Those LVH+ and cTnT+ and/or NT-proBNP+ (n = 144) were older and more likely to be male, with a greater risk factor burden and more severe LVH compared with those who were LVH+ biomarker– (p < 0.01 for each). The cumulative incidence of HF or CV death over 8 years among LVH+ cTnT+ was 21% versus 1% (LVH– cTnT–), 4% (LVH– cTnT+), and 6% (LVH+ cTnT–) (p < 0.0001). The interactions between LVH and cTnT (pinteraction = 0.0005) and LVH and NT-proBNP (pinteraction = 0.014) were highly significant. Individuals who were LVH+ and either cTnT+ or NT-proBNP+ remained at >4-fold higher risk for HF or CV death after multivariable adjustment for CV risk factors, renal function, and LV mass compared with those who were LVH– biomarker–. Conclusions: Minimal elevations in biomarkers of subclinical cardiac injury and hemodynamic stress modify the association of LVH with adverse outcomes, identifying a malignant subphenotype of LVH with high risk for progression to HF and CV death. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.